RBC Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $21 from $25 and keeps an Outperform rating on the shares. Enrollment in the company’s cardiomyopathy treatment trial continues to outpace internal target projections, and the company announced they are increasing the size of the trial from 765 to 1,200, the analyst tells investors in a research note. The firm added that its new price target reflects Intellia’s quarterly results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Announces Executive Retirement
- Intellia Therapeutics reports Q2 EPS (98c), consensus ($1.01)
- Intellia Therapeutics sees cash runway into 1H27
- Intellia Therapeutics announces employee inducement grants
- Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN